RE: Elliott Management’s stake in GSK: Doomsday beckons for Walmsley16 Apr 2021 13:45
PC..
This section "Michael Hewson, chief market analyst at CMC Markets UK, said: “This activist shareholder has a track record of shaking things up and Glaxo shares have seriously underperformed the wider market for several years. Earlier this year they hit their lowest levels in a decade, with the company being increasingly left behind by its peers AstraZeneca and Pfizer.”
So if one studys Pfizer there share price is lower now than it was 3 years ago, its dividend during that time as been 50% of GSK dividend, even now with its supposed revenue from Vaccine, its still lagging where it was a year ago.